Bristol-Myers Squibb (BMY) SEC Filings: History & Chart

Bristol-Myers Squibb Company(BMY)

Drug Manufacturers - General · Princeton, NJ

$65.14-1.69 (-2.52%)

Delayed quote: Sep 8, 2026, 11:00 AM EDT

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ

32,500 employees

www.bms.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher Boerner

View full financials

Form	Filing Date	Accepted	Document
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Aug 26, 2026	Aug 26, 2026	View filing
SC 13G	Aug 7, 2026	Aug 7, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
10-Q	Jul 30, 2026	Jul 30, 2026	View filing
8-K	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jun 16, 2026	Jun 16, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
11-K	Jun 5, 2026	Jun 5, 2026	View filing
11-K	Jun 5, 2026	Jun 5, 2026	View filing
11-K	Jun 5, 2026	Jun 5, 2026	View filing
S-8	May 8, 2026	May 8, 2026	View filing
8-K	May 8, 2026	May 8, 2026	View filing
4	May 5, 2026	May 5, 2026	View filing
10-Q	Apr 30, 2026	Apr 30, 2026	View filing
8-K	Apr 30, 2026	Apr 30, 2026	View filing
SC 13G	Apr 29, 2026	Apr 29, 2026	View filing
DEFA14A	Apr 17, 2026	Apr 17, 2026	View filing
4	Apr 2, 2026	Apr 2, 2026	View filing
4	Apr 2, 2026	Apr 2, 2026	View filing
4	Apr 2, 2026	Apr 2, 2026	View filing
4	Apr 2, 2026	Apr 2, 2026	View filing
4	Apr 2, 2026	Apr 2, 2026	View filing
4	Apr 2, 2026	Apr 2, 2026	View filing

SEC Filings

Recent Filings